| Status: Recommended | ||
Maraviroc (Celsentri®) is recommended as an option for use within NHS Wales for the treatment of treatment-experienced adults infected only with CCR5-tropic HIV-1, in accordance with British HIV Association (BHIVA) guidance. AWMSG is of the opinion that maraviroc (Celsentri®) is not suitable for shared care within NHS Wales. |
||
|
||
Medicine details |
||
| Medicine name | maraviroc (Celsentri®) | |
| Formulation | film-coated tablet | |
| Reference number | 344 | |
| Indication | In combination with other antiretroviral medicinal products for treatment of treatment-experienced adult patients infected with only CCR5-tropic HIV-1 detectable |
|
| Company | Pfizer Ltd | |
| BNF chapter | Infections | |
| Submission type | Resubmission | |
| Status | Recommended | |
| Advice number | 0709 | |
| NMG meeting date | 25/03/2009 | |
| AWMSG meeting date | 29/04/2009 | |
| Ratification by Welsh Government | 10/06/2009 | |
| Date of issue | 11/06/2009 | |